PITTSBURGH - Krystal Biotech, Inc. (the 'Company') (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 44th Annual Health Care Conference, which takes place in Boston on March 4-6.

Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at 9:50 am ET during the conference and host investor meetings on March 5.

A webcast of the presentation will be available here beginning at 9:50 am ET on Tuesday, March 5 and will be posted on the Investors section of the Company's website.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.

Contact:

Meg Dodge

Email: mdodge@krystalbio.com

(C) 2024 Electronic News Publishing, source ENP Newswire